Sorbitol risks liver health in sugar-free products
Research suggests sorbitol can be converted into harmful fructose-related compounds in the liver, challenging the health profile of common sugar-free food…

Recent research indicates that sorbitol, a widely used sugar alcohol in low-calorie food products, may pose metabolic risks previously attributed only to fructose. The human body can convert sorbitol into fructose-related compounds within the liver, potentially contributing to steatotic liver disease and other metabolic complications.
Intestinal enzymes can synthesize sorbitol from glucose even in non-diabetic individuals, depending on dietary intake levels. While specific gut bacteria can degrade sorbitol into harmless byproducts, high consumption of glucose or sorbitol can overwhelm this microbial defense mechanism.
These findings suggest that current labeling of "sugar-free" products may not guarantee the intended health outcomes for consumers managing metabolic conditions. The potential for systemic conversion of sugar substitutes into harmful metabolites necessitates a reevaluation of dietary guidelines regarding polyol intake and its impact on long-term metabolic health.
More stories
- Cochrane seeks Nov. 30 bids for adult pneumococcal vaccine review
- Athlete eye-balance screens may move beyond concussion rehab
- Conflict-zone athletes face sleep stress standard plans miss
- Tai Chi may ease pain in musculoskeletal disorders
- Peptide access push may obscure patient harm reports
- ACL graft choice shows no revision link in Swedish football study
- Scientists Just Found 824 New 'Personality Genes' — But the Real Shocker Is What They Ruled Out
- Guinea-Bissau health officials report seven confirmed mpox cases
Latest news
- Bonfiglioli Transmissions IPO to cut promoter stake to 77%
- Faraday gives BHP 32% stake in San Manuel deal
- Istanbul flooding prompts school closures and road bans
- Trump halts execution livestream plan after backlash grows
- Albania protests intensify as Rama rejects calls to resign
- Zampolli loses envoy post after reported diplomatic feud
- Anthropic IPO plans take focus as smaller US deals stall
- US official denies Trump Starshield restriction directive

